Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

LATS1/2-inactivation and consequent nuclear YAP/TAZ hyperactivation in the mammary epithelium drives the development of a pro ...

Perpetual’s directors have been summoned to a board meeting scheduled for late Tuesday, as KKR prepares to rejig a $2.2 billion bid that was stung by a hefty tax bill.